Misplaced Pages

Tarextumab (formerly OMP-59R5) is a fully human monoclonal antibody targeting the Notch 2/3 receptors. It is being tested as a possible treatment for cancer. In January 2015, the US FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and lung cancer. Two early stage clinical trials have reported encouraging results.

See also

• Notch signaling pathway, e.g. in embryo tissue development

References

1. ^ "Tarextumab Gets FDA Orphan Drug Designation for Lung, Pancreatic Cancer". 2015.

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Pharmacology stubs
• Experimental cancer drugs
• Monoclonal antibodies